These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29228091)

  • 21. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
    Aapro M; Tjulandin S; Bhar P; Gradishar W
    Breast; 2011 Oct; 20(5):468-74. PubMed ID: 21843943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials.
    Bernardo A; Palumbo R; Pedersini R; Rota Caremoli E; Gambaro AR; Ferzi A; Riva F; Grasso D; Danova M; Tarenzi E; Torri V; Cazzaniga ME
    Clin Breast Cancer; 2017 Oct; 17(6):433-440. PubMed ID: 28366406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
    Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Tsurutani J; Hara F; Kitada M; Takahashi M; Kikawa Y; Kato H; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Taira N; Takashima T; Kashiwabara K; Aihara T; Mukai H
    Breast; 2021 Feb; 55():63-68. PubMed ID: 33341707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
    Lobo C; Lopes G; Baez O; Castrellon A; Ferrell A; Higgins C; Hurley E; Hurley J; Reis I; Richman S; Seo P; Silva O; Slingerland J; Tukia K; Welsh C; Glück S
    Breast Cancer Res Treat; 2010 Sep; 123(2):427-35. PubMed ID: 20585851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
    Yardley DA; Hart L; Bosserman L; Salleh MN; Waterhouse DM; Hagan MK; Richards P; DeSilvio ML; Mahoney JM; Nagarwala Y
    Breast Cancer Res Treat; 2013 Jan; 137(2):457-64. PubMed ID: 23224144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).
    Kobayashi D; Mochizuki Y; Torii K; Takeda S; Kawase Y; Ishigure K; Teramoto H; Ando M; Kodera Y
    Int J Clin Oncol; 2020 Oct; 25(10):1793-1799. PubMed ID: 32567012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
    Jain MM; Gupte SU; Patil SG; Pathak AB; Deshmukh CD; Bhatt N; Haritha C; Govind Babu K; Bondarde SA; Digumarti R; Bajpai J; Kumar R; Bakshi AV; Bhattacharya GS; Patil P; Subramanian S; Vaid AK; Desai CJ; Khopade A; Chimote G; Bapsy PP; Bhowmik S
    Breast Cancer Res Treat; 2016 Feb; 156(1):125-34. PubMed ID: 26941199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
    Liang C; Li L; Fraser CD; Ko A; Corzo D; Enger C; Patt D
    BMC Cancer; 2015 Dec; 15():1019. PubMed ID: 26714468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
    Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
    Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.
    Lu H; Zha S; Zhang W; Wang Q; Jiang D; Xu X; Zheng X; Qiu M; Shan C
    BMC Cancer; 2021 Jul; 21(1):830. PubMed ID: 34275458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.
    Yoshimura N; Sawa K; Nakai T; Matsumoto Y; Mitsuoka S; Kimura T; Asai K; Yana T; Kawaguchi T; Hirata K
    Am J Clin Oncol; 2021 Dec; 44(12):613-618. PubMed ID: 34753884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
    Sakata S; Saeki S; Okamoto I; Otsubo K; Komiya K; Morinaga R; Yoneshima Y; Koga Y; Enokizu A; Kishi H; Hirosako S; Yamaguchi E; Aragane N; Fujii S; Harada T; Iwama E; Semba H; Nakanishi Y; Kohrogi H
    Lung Cancer; 2016 Sep; 99():41-5. PubMed ID: 27565912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
    Potthoff K; Stötzer O; Söling U; Hansen R; Harde J; Dille S; Nusch A; Marschner N
    Clin Breast Cancer; 2020 Jun; 20(3):e315-e326. PubMed ID: 32273207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.
    Liu Z; Wei Z; Hu Y; Gao F; Hao L; Fang P; Sun S; Li J; Jiao S
    Med Oncol; 2015 Aug; 32(8):216. PubMed ID: 26168982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.